year, the Secretary shall include in the report an analysis of the following: (A) The difference between the number of biosimilar biological product applications and supplements filed and the number of approvals or complete response letters issued by the agency, accounting for— (i) such applications filed during one fiscal year for which a decision is not scheduled to be made until the following fiscal year